1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Particle Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Particle Therapy Market, by Type
8.1.1. Proton Therapy
8.1.1.1. Market Revenue and Forecast
8.1.2. Heavy Ion Therapy
8.1.2.1. Market Revenue and Forecast
9.1. Particle Therapy Market, by System
9.1.1. Single Room Systems
9.1.1.1. Market Revenue and Forecast
9.1.2. Multi-room Systems
9.1.2.1. Market Revenue and Forecast
10.1. Particle Therapy Market, by Application
10.1.1. Treatment
10.1.1.1. Market Revenue and Forecast
10.1.2. Clinical Research
10.1.2.1. Market Revenue and Forecast
11.1. Particle Therapy Market, by Cancer Type
11.1.1. Pediatric Cancer
11.1.1.1. Market Revenue and Forecast
11.1.2. Breast Cancer
11.1.2.1. Market Revenue and Forecast
11.1.3. Lung Cancer
11.1.3.1. Market Revenue and Forecast
11.1.4. Head and Neck Cancer
11.1.4.1. Market Revenue and Forecast
11.1.5. Others
11.1.5.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Type
12.1.2. Market Revenue and Forecast, by System
12.1.3. Market Revenue and Forecast, by Application
12.1.4. Market Revenue and Forecast, by Cancer Type
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Type
12.1.5.2. Market Revenue and Forecast, by System
12.1.5.3. Market Revenue and Forecast, by Application
12.1.5.4. Market Revenue and Forecast, by Cancer Type
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Type
12.1.6.2. Market Revenue and Forecast, by System
12.1.6.3. Market Revenue and Forecast, by Application
12.1.6.4. Market Revenue and Forecast, by Cancer Type
12.2. Europe
12.2.1. Market Revenue and Forecast, by Type
12.2.2. Market Revenue and Forecast, by System
12.2.3. Market Revenue and Forecast, by Application
12.2.4. Market Revenue and Forecast, by Cancer Type
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Type
12.2.5.2. Market Revenue and Forecast, by System
12.2.5.3. Market Revenue and Forecast, by Application
12.2.5.4. Market Revenue and Forecast, by Cancer Type
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Type
12.2.6.2. Market Revenue and Forecast, by System
12.2.6.3. Market Revenue and Forecast, by Application
12.2.6.4. Market Revenue and Forecast, by Cancer Type
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Type
12.2.7.2. Market Revenue and Forecast, by System
12.2.7.3. Market Revenue and Forecast, by Application
12.2.7.4. Market Revenue and Forecast, by Cancer Type
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Type
12.2.8.2. Market Revenue and Forecast, by System
12.2.8.3. Market Revenue and Forecast, by Application
12.2.8.4. Market Revenue and Forecast, by Cancer Type
12.3. APAC
12.3.1. Market Revenue and Forecast, by Type
12.3.2. Market Revenue and Forecast, by System
12.3.3. Market Revenue and Forecast, by Application
12.3.4. Market Revenue and Forecast, by Cancer Type
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Type
12.3.5.2. Market Revenue and Forecast, by System
12.3.5.3. Market Revenue and Forecast, by Application
12.3.5.4. Market Revenue and Forecast, by Cancer Type
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Type
12.3.6.2. Market Revenue and Forecast, by System
12.3.6.3. Market Revenue and Forecast, by Application
12.3.6.4. Market Revenue and Forecast, by Cancer Type
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Type
12.3.7.2. Market Revenue and Forecast, by System
12.3.7.3. Market Revenue and Forecast, by Application
12.3.7.4. Market Revenue and Forecast, by Cancer Type
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Type
12.3.8.2. Market Revenue and Forecast, by System
12.3.8.3. Market Revenue and Forecast, by Application
12.3.8.4. Market Revenue and Forecast, by Cancer Type
12.4. MEA
12.4.1. Market Revenue and Forecast, by Type
12.4.2. Market Revenue and Forecast, by System
12.4.3. Market Revenue and Forecast, by Application
12.4.4. Market Revenue and Forecast, by Cancer Type
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Type
12.4.5.2. Market Revenue and Forecast, by System
12.4.5.3. Market Revenue and Forecast, by Application
12.4.5.4. Market Revenue and Forecast, by Cancer Type
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Type
12.4.6.2. Market Revenue and Forecast, by System
12.4.6.3. Market Revenue and Forecast, by Application
12.4.6.4. Market Revenue and Forecast, by Cancer Type
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Type
12.4.7.2. Market Revenue and Forecast, by System
12.4.7.3. Market Revenue and Forecast, by Application
12.4.7.4. Market Revenue and Forecast, by Cancer Type
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Type
12.4.8.2. Market Revenue and Forecast, by System
12.4.8.3. Market Revenue and Forecast, by Application
12.4.8.4. Market Revenue and Forecast, by Cancer Type
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Type
12.5.2. Market Revenue and Forecast, by System
12.5.3. Market Revenue and Forecast, by Application
12.5.4. Market Revenue and Forecast, by Cancer Type
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Type
12.5.5.2. Market Revenue and Forecast, by System
12.5.5.3. Market Revenue and Forecast, by Application
12.5.5.4. Market Revenue and Forecast, by Cancer Type
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Type
12.5.6.2. Market Revenue and Forecast, by System
12.5.6.3. Market Revenue and Forecast, by Application
12.5.6.4. Market Revenue and Forecast, by Cancer Type
13.1. Ion Beam Applications S.A.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Varian Medical Systems
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Hitachi, Ltd.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Mevion Medical Systems, Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Sumitomo Heavy Industries, Ltd.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Mitsubishi Electric Corporation
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Toshiba Energy Systems and Solutions
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. ProTom International, Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Advanced Oncotherapy plc
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. P-Cure Ltd.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
